Related references
Note: Only part of the references are listed.Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease
Jayasankar Kosaraju et al.
MOLECULAR NEUROBIOLOGY (2017)
DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice
Yu Hasegawa et al.
CARDIOVASCULAR DIABETOLOGY (2017)
The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy
Henrik H. Hansen et al.
BRAIN RESEARCH (2016)
Type 2 Diabetes Mellitus and Alzheimer's Disease: Bridging the Pathophysiology and Management
Fahmida Alam et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes
Trevor Hardigan et al.
LIFE SCIENCES (2016)
DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice
MingJie Ma et al.
CARDIOVASCULAR DIABETOLOGY (2015)
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline
V. A. Gault et al.
DIABETES OBESITY & METABOLISM (2015)
A Novel Mouse Model of Subcortical Infarcts with Dementia
Yorito Hattori et al.
JOURNAL OF NEUROSCIENCE (2015)
Cognitive function in patients with diabetes mellitus: guidance for daily care
Paula S. Koekkoek et al.
LANCET NEUROLOGY (2015)
A review on Alzheimer's disease pathophysiology and its management: an update
Anil Kumar et al.
PHARMACOLOGICAL REPORTS (2015)
Aberrant insulin signaling in Alzheimer's disease: current knowledge
Gaurav Bedse et al.
FRONTIERS IN NEUROSCIENCE (2015)
The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease
Konrad Talbot et al.
ALZHEIMERS & DEMENTIA (2014)
Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease
Mark Yarchoan et al.
DIABETES (2014)
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease
Paula L. McClean et al.
NEUROPHARMACOLOGY (2014)
Insulin dysfunction and Tau pathology
Noura B. El Khoury et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2014)
Insulin as a bridge between type 2 diabetes and Alzheimer disease - how anti-diabetics could be a solution for dementia
Ines Sebastiao et al.
FRONTIERS IN ENDOCRINOLOGY (2014)
Detrimental Effects of Diet-Induced Obesity on τ Pathology Are Independent of Insulin Resistance in τ Transgenic Mice
Antoine Leboucher et al.
DIABETES (2013)
The Diabetes Drug Liraglutide Ameliorates Aberrant Insulin Receptor Localisation and Signalling in Parallel with Decreasing Both Amyloid-β Plaque and Glial Pathology in a Mouse Model of Alzheimer's Disease
Caitriona M. Long-Smith et al.
NEUROMOLECULAR MEDICINE (2013)
Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition
Swenja Kroeller-Schoen et al.
CARDIOVASCULAR RESEARCH (2012)
Lipid Sensing and Insulin Resistance in the Brain
Jessica T. Y. Yue et al.
CELL METABOLISM (2012)
Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures
Dong-Hou Kim et al.
NEUROBIOLOGY OF DISEASE (2012)
The pathological process underlying Alzheimer's disease in individuals under thirty
Heiko Braak et al.
ACTA NEUROPATHOLOGICA (2011)
Novel GLP-1 Mimetics Developed To Treat Type 2 Diabetes Promote Progenitor Cell Proliferation in the Brain
A. Hamilton et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2011)
Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes
Amit Gupta et al.
NEUROPHARMACOLOGY (2011)
Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection
Alexander Harkavyi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Insulin resistance and Alzheimer's disease
Suzanne M. de la Monte
BMB REPORTS (2009)
Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model
Erik D. Roberson et al.
SCIENCE (2007)
Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model
Yasumasa Yoshiyama et al.
NEURON (2007)
GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes
B Ahrén et al.
HORMONE AND METABOLIC RESEARCH (2004)
Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics
J Hardy et al.
SCIENCE (2002)
Share Paper
